Fig. 4

The mean concentration changes of the complement activation markers during the first 6 months of the transplantation period. Allogeneic and autologous patients shown separately, number of patients is given. (A) The mean concentration of C3a. (B) The mean concentration of SC5b-9. The one allo-patient (Patient 3, cf. Fig. 3) with extremely high SC5b-9 levels separating strongly from all the other patients was excluded from the analysis.